Ingenol mebutate
- Generic Name
- Ingenol mebutate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 75567-37-2
- Unique Ingredient Identifier
- 7686S50JAH
- Background
Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis. Before approval, ingenol mebutate was called PEP005 as an investigational drug. PEP005 is a selective small molecule activator of protein kinase C (PKC) extracted from the plant Euphorbia...
- Indication
For the topical treatment of actinic keratosis.
- Associated Conditions
- Actinic Keratosis (AK)
- Associated Therapies
- -
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 266
- Registration Number
- NCT01998984
- Locations
- 🇺🇸
Long Island Skin Cancer and Dermatologic Surgery, Smithtown, New York, United States
Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions
Early Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT01735942
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
- First Posted Date
- 2011-10-10
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 24
- Registration Number
- NCT01449513
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath